Patrick Marcellin

Summary

Country: France

Publications

  1. ncbi request reprint Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study
    Patrick Marcellin
    Service Hepato Gastroenterology, Hopital Beaujon, Paris, France
    Antivir Ther 19:235-43. 2014
  2. doi request reprint Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal
    Patrick Marcellin
    Service d Hepatologie, Hopital Beaujon, University of Paris, Clichy, France
    J Gastroenterol Hepatol 28:912-23. 2013
  3. doi request reprint Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
    Patrick Marcellin
    Service d Hepatologie, Hopital Beaujon, INSERM Unit CRB3, Clichy, France
    Lancet 381:468-75. 2013
  4. doi request reprint Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies
    Patrick Marcellin
    Hopital Beaujon, 100 Boulevard du General Leclerc, Clichy, 92110, France
    Expert Opin Drug Saf 11:901-9. 2012
  5. doi request reprint Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University of Paris, Hopital Beaujon, Pavillon Abrami, 100 Boulevard Général Leclerc, 92110 Clichy, France
    J Hepatol 56:1276-82. 2012
  6. doi request reprint [Hepatitis C: the recovery]
    P Marcellin
    INSERM U773 CRB3, Service d Hepatologie, Universite de Paris 7, Hopital Beaujon, 92110 Clichy, France
    Gastroenterol Clin Biol 33:819-29. 2009
  7. doi request reprint Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
    Patrick Marcellin
    Hopital Beaujon, Paris, France
    Hepatology 48:750-8. 2008
  8. doi request reprint Hepatitis B and hepatitis C in 2009
    Patrick Marcellin
    Service d Hepatologie, AP HP and INSERM U773, Centre de Recherche Biologique Bichat Beaujon CRB3, Universite Denis Diderot Paris 7, Hopital Beaujon, Clichy, France
    Liver Int 29:1-8. 2009
  9. ncbi request reprint [HCV non-responder patients: definition of non-response and treatment strategy]
    Patrick Marcellin
    Service d Hepatologie, INSERM U773 CRB3, Universite Paris VII, Hopital Beaujon, Clichy, France
    Gastroenterol Clin Biol 31:4S13-9. 2007
  10. doi request reprint Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon
    Patrick Marcellin
    Service d Hepatologie, INSERM CRB3, Hopital Beaujon, APHP University of Paris 7, Clichy, France
    Liver Int 30:657-68. 2010

Collaborators

Detail Information

Publications96

  1. ncbi request reprint Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study
    Patrick Marcellin
    Service Hepato Gastroenterology, Hopital Beaujon, Paris, France
    Antivir Ther 19:235-43. 2014
    ..This prospective, longitudinal, non-interventional study aimed to assess differences in CHB management in five European countries (Germany, France, Poland, Romania and Turkey)...
  2. doi request reprint Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal
    Patrick Marcellin
    Service d Hepatologie, Hopital Beaujon, University of Paris, Clichy, France
    J Gastroenterol Hepatol 28:912-23. 2013
    ....
  3. doi request reprint Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
    Patrick Marcellin
    Service d Hepatologie, Hopital Beaujon, INSERM Unit CRB3, Clichy, France
    Lancet 381:468-75. 2013
    ..We aimed to assess the effects on fibrosis and cirrhosis of at least 5 years' treatment with tenofovir disoproxil fumarate (DF) in chronic HBV infection...
  4. doi request reprint Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies
    Patrick Marcellin
    Hopital Beaujon, 100 Boulevard du General Leclerc, Clichy, 92110, France
    Expert Opin Drug Saf 11:901-9. 2012
    ..This analysis examines the safety profile of standard- versus high-dose peginterferon alfa-2a...
  5. doi request reprint Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University of Paris, Hopital Beaujon, Pavillon Abrami, 100 Boulevard Général Leclerc, 92110 Clichy, France
    J Hepatol 56:1276-82. 2012
    ....
  6. doi request reprint [Hepatitis C: the recovery]
    P Marcellin
    INSERM U773 CRB3, Service d Hepatologie, Universite de Paris 7, Hopital Beaujon, 92110 Clichy, France
    Gastroenterol Clin Biol 33:819-29. 2009
    ....
  7. doi request reprint Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
    Patrick Marcellin
    Hopital Beaujon, Paris, France
    Hepatology 48:750-8. 2008
    ..Adefovir resistance mutations A181V or N236T developed in 13 LTSES patients; the first observation was at study week 195. There were no serious adverse events related to ADV...
  8. doi request reprint Hepatitis B and hepatitis C in 2009
    Patrick Marcellin
    Service d Hepatologie, AP HP and INSERM U773, Centre de Recherche Biologique Bichat Beaujon CRB3, Universite Denis Diderot Paris 7, Hopital Beaujon, Clichy, France
    Liver Int 29:1-8. 2009
    ..Furthermore, considerable progress has been made in the efficacy of therapy. New drugs and new therapeutic strategies that are currently under evaluation could further improve the efficacy of therapy in the near future...
  9. ncbi request reprint [HCV non-responder patients: definition of non-response and treatment strategy]
    Patrick Marcellin
    Service d Hepatologie, INSERM U773 CRB3, Universite Paris VII, Hopital Beaujon, Clichy, France
    Gastroenterol Clin Biol 31:4S13-9. 2007
    ..The drugs, currently in phase 1 and 2, which will demonstrate their efficacy and safety, should not be available before several years...
  10. doi request reprint Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon
    Patrick Marcellin
    Service d Hepatologie, INSERM CRB3, Hopital Beaujon, APHP University of Paris 7, Clichy, France
    Liver Int 30:657-68. 2010
    ....
  11. doi request reprint A personalized approach to optimize hepatitis B treatment in treatment-naive patients
    Patrick Marcellin
    Service d Hepatologie, Hopital Beaujon, AP HP, Clichy, France
    Antivir Ther 15:53-9. 2010
    ....
  12. doi request reprint Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study
    Patrick Marcellin
    Department of Hepatology, University of Paris 7, INSERM U 773, CRB3, Beaujon Hospital, Clichy, France
    Liver Int 31:516-24. 2011
    ..Adherence is important for therapy of chronic diseases, but has still not been well studied in real life in chronic hepatitis C...
  13. doi request reprint Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, Hopital Beaujon, APHP, Universite Denis Diderot Paris 7, Clichy, France
    Gastroenterology 140:459-468.e1; quiz e14. 2011
    ..We investigated the efficacy, safety, tolerability, and pharmacokinetics of telaprevir given q8h or every 12 hours (q12 h) in combination with peginterferon alfa-2a or alfa-2b...
  14. doi request reprint Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a
    Patrick Marcellin
    Service d Hepatologie, U773 CRB3, Hopital Beaujon, University of Paris, Clichy, France
    Gastroenterology 136:2169-2179.e1-4. 2009
    ..The durability of <or=3-year posttreatment response was investigated in this study...
  15. doi request reprint Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis
    Ana Carolina Cardoso
    Service d Hepatologie, Hopital Beaujon, AP HP, INSERM U773 CRB3, Universite Denis Diderot Paris7, 100 Boulevard du General Leclerc, 92110 Clichy, France
    J Hepatol 52:652-7. 2010
    ..We assessed the influence of combination therapy on the risk of HCC, liver-related complications (ascites, variceal bleeding), and liver-related death (or liver transplantation)...
  16. ncbi request reprint [Treatment of chronic hepatitis B]
    Tarik Asselah
    Service d Hepatologie, INSERM CRB3, Universite Paris VII, Hopital Beaujon, Clichy 92
    Presse Med 35:327-34. 2006
    ..They induce a sustained response after withdrawal of therapy in only a minority of patients and therefore the treatment needs to be indefinitely administered in the majority of patients...
  17. pmc Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C
    Emilie Estrabaud
    INSERM, UMR1149, Team Physiopathology and Treatment of Viral Hepatitis, Centre de Recherche sur l Inflammation, BP 416, Paris, France
    J Virol 88:6394-402. 2014
    ..The association between miR-122 and IFNL3 was stronger than the association between miR-122 and response to treatment. miR-122 may play a role in the early viral decline that is dependent on IFNL3 and the innate immune response...
  18. doi request reprint Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, Clichy, France
    Antivir Ther 14:1183-8. 2009
    ....
  19. doi request reprint Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin
    Michelle Martinot-Peignoux
    Institut National de la Sante et de la Recherche Medicale, U 773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Universite Paris VII, Paris, France
    Hepatology 51:1122-6. 2010
    ..7%), is as relevant as after 24 weeks to predict SVR and make decisions on the management of treated patients, suggesting a new definition for SVR...
  20. ncbi request reprint Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin
    Valerie Paradis
    Service d anatomie pathologie, Hopital Beaujon, and CNRS UMR 8149, Clichy, France
    Gastroenterology 130:2189-97. 2006
    ..We used this approach to monitor the kinetics of serum proteome in patients with chronic hepatitis C virus infection receiving a standard bitherapy regimen to predict treatment response...
  21. ncbi request reprint Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1
    Lawrence Serfaty
    Service d Hépatologie and INSERM UMRS 938, Hopital Saint Antoine, Universite Pierre and Marie Curie, Paris, France
    Gut 61:1473-80. 2012
    ..This exploratory analysis assessed the effect of metabolic factors and insulin resistance, measured by homoeostatic model assessment (HOMA), on virological response to telaprevir in Study C208...
  22. doi request reprint Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
    Rami Moucari
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    Hepatology 49:1151-7. 2009
    ..HBsAg loss was observed in three patients, all with SVR...
  23. doi request reprint Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, Clichy F 92110, France
    Gastroenterology 134:416-23. 2008
    ..Our study was designed to test the association between insulin resistance (IR) and hepatitis C virus (HCV) genotypes, serum HCV RNA level and liver fibrosis stage in a large prospective cohort of chronic hepatitis C (CHC) patients...
  24. doi request reprint Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University of Paris, Hopital Beaujon, Clichy, France
    Liver Int 28:477-85. 2008
    ..Pooled data from five studies of peginterferon alpha-2a in patients with chronic HCV infection (CHC) were compared with two studies of the drug in patients with chronic HBV infection (CHB)...
  25. ncbi request reprint High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy
    Rami Moucari
    Service d hépatologie and INSERM CRB3, Hopital Beaujon, AP HP, Universite Paris VII, Clichy, France
    J Hepatol 46:596-604. 2007
    ..To evaluate the efficacy of peginterferon alfa-2b and ribavirin in unselected consecutive patients with chronic hepatitis C, treated outside of trials, who were relapsers or non-responders to interferon and ribavirin combination...
  26. pmc Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody
    Sarah Maylin
    Service de Microbiologie, Hopital Beaujon, Clichy, France
    Liver Int 29:511-7. 2009
    ..Viral eradication in chronic hepatitis C patients with sustained virological response (SVR) after interferon (IFN) therapy remains controversial...
  27. doi request reprint Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C
    Sarah Maylin
    Universite Paris VII, Hopital Beaujon, Clichy, France
    Gastroenterology 135:821-9. 2008
    ..It is unclear whether hepatitis C virus (HCV) is eradicated in patients with chronic hepatitis C who achieved a sustained virologic response (SVR)...
  28. ncbi request reprint Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin
    Michelle Martinot-Peignoux
    INSERM, U 773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Universite Paris VII, Hopital Beaujon, Clichy, France
    Antivir Ther 14:501-11. 2009
    ....
  29. doi request reprint High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, 100 Boulevard du General Leclerc, 92100 Clichy, France
    J Hepatol 50:1084-92. 2009
    ..To assess the HBsAg seroconversion rate and its impact on the long-term outcome in chronic hepatitis B patients treated with conventional interferon, and to analyze the serum HBsAg concentration prior to seroconversion...
  30. ncbi request reprint Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
    Patrick Marcellin
    Hopital Beaujon, Assistance Publique Hopitaux de Paris, University of Paris 7 and INSERM Unité 773, Centre de Recherches Claude Bernard sur les Hepatites Virales, Clichy, France
    N Engl J Med 359:2442-55. 2008
    ..Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase...
  31. doi request reprint Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA
    Michelle Martinot-Peignoux
    Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U 773, Universite Paris Diderot, 92110 Clichy, France Electronic address
    J Clin Virol 58:401-7. 2013
    ..We investigated whether serum-based monitoring of hepatitis B surface antigen (HBsAg) and HBV-DNA in asymptomatic HBeAg(-) patients could distinguish these groups...
  32. doi request reprint Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir
    Olivier Lada
    Service d Hépatologie and INSERM U773 CRB3, AP HP Hôpital Beaujon, Clichy, France
    Antivir Ther 17:61-70. 2012
    ..The present study was performed to evaluate the quasispecies variability and the in vitro drug susceptibility to approved antiviral drugs of HBV genomes directly isolated from patients' sera...
  33. pmc Impact of ribavirin dose on retreatment of chronic hepatitis C patients
    Christiane Stern
    Service d Hépatologie and INSERM U773 CRB3, Hopital Beaujon, University Paris Diderot, 92110 Clichy, France
    World J Gastroenterol 18:2966-72. 2012
    ..To study the efficacy and factors associated with a sustained virological response (SVR) in chronic hepatitis C (CHC) relapsing patients...
  34. ncbi request reprint Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, INSERM Unité 481 and Centre de Recherches Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    N Engl J Med 351:1206-17. 2004
    ..As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications...
  35. ncbi request reprint Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C
    Michelle Martinot-Peignoux
    INSERM, U 773, Centre de Recherche Biomédicale Bichat Beaujon CRB3 and Service d Hépatologie, Hopital Beaujon, AP HP, Universite Paris 7, 92110 Clichy, France
    J Clin Virol 46:216-21. 2009
    ..Early viral monitoring is essential for the management of treatment outcome in patients with chronic hepatitis C. A variety of commercially available assays are now available to quantify HCV-RNA in routine clinical practice...
  36. ncbi request reprint Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection
    Pierre Emmanuel Rautou
    Service d hépatologie and INSERM CRB3, University of Paris VII, Hopital Beaujon, Clichy, France
    Eur J Gastroenterol Hepatol 18:1019-22. 2006
    ..We conclude that the combination of PegIFN plus ribavirin may induce suppression of both viral infections...
  37. doi request reprint The role of HBsAg quantification for monitoring natural history and treatment outcome
    Michelle Martinot-Peignoux
    INSERM, U 773, CRB3, Universite Paris Diderot, Hopital Beaujon, Clichy, France
    Liver Int 33:125-32. 2013
    ..In clinical practice, HBsAg quantification is a simple and reproducible tool that can be used in association with HBV DNA to classify patients during the natural history of HBV and to monitor therapy...
  38. doi request reprint Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy
    Sarah Maylin
    Service de Microbiologie, Universite Paris VII, Faculté de Médecine Denis Diderot, Hopital Bichat, Paris, France
    J Clin Virol 53:43-7. 2012
    ..Correlation between hepatic HCV-RNA and serum HCV-RNA, severity of liver disease and response to therapy is poorly known...
  39. doi request reprint Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response
    Dan Avi Landau
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, Paris, France
    Arthritis Rheum 58:604-11. 2008
    ....
  40. ncbi request reprint Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study
    Pierre Bedossa
    Service d Anatomie Pathologique, CNRS UMR 8149, Clichy, France
    Hepatology 46:380-7. 2007
    ..In multivariate analysis, triglyceride and HDL cholesterol were predictors of NASH in patients with genotype 1, whereas in patients with genotype 3, AST was the only predictor...
  41. doi request reprint Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
    Christophe Hezode
    Department of Hepatology and Gastroenterology, Hopital Henri Mondor, AP HP, Universite Paris Est, INSERM U955, Creteil, France
    J Hepatol 59:434-41. 2013
    ..We report the week 16 safety and efficacy analysis in a cohort of compensated cirrhotics treated in the French Early Access Programme...
  42. ncbi request reprint Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B
    Vincent Di Martino
    Service d Hepatologie, INSERM U481 et Centre de Recherche Claude Bernard sur les hépatites virales, Hôpital Beaujon AP HP, Clichy, France
    Gastroenterology 123:1812-22. 2002
    ..We analyzed the influence of HIV coinfection on the response to IFN-alpha therapy, long-term virologic status, progression to cirrhosis, and mortality...
  43. ncbi request reprint Role of replicative senescence in the progression of fibrosis in hepatitis C virus (HCV) recurrence after liver transplantation
    Viviane Trak-Smayra
    Service d Anatomie Pathologique, Hopital Beaujon, Clichy, France
    Transplantation 77:1755-60. 2004
    ....
  44. doi request reprint IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C
    Tarik Asselah
    Hepatology Department, AP HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, France
    J Hepatol 56:527-32. 2012
    ..However, there are few data on HCV genotype 4 (HCV-4) infection. We evaluated, in a unique well-characterized cohort of HCV-4 patients, the association of IL28B polymorphism with response to treatment or liver disease severity...
  45. ncbi request reprint In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C
    Tarik Asselah
    INSERM U773, Centre de Recherche CRB3, Paris, 75018, France
    J Pathol 221:264-74. 2010
    ..This lack of gene induction may be explained by the inhibiting action of HCV per se (as suggested by in vitro studies) and/or by our finding of the localized nature of hepatocyte ER stress...
  46. doi request reprint Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients
    Patrick Marcellin
    Hopital Beaujon, Clichy, France
    J Hepatol 52:32-8. 2010
    ..Viramidine is associated with a lower incidence of anemia because of its liver-targeting properties...
  47. pmc Significant gene expression differences in histologically "Normal" liver biopsies: Implications for control tissue
    Tarik Asselah
    Service d Hépatologie and Institut National de la Santé et de la Recherche Médicale INSERM U733, CRB3, Universite Paris Diderot, Assistance Publique Hopitaux de Paris, Hopital Beaujon, Clichy, France
    Hepatology 48:953-62. 2008
    ..In chronic hepatitis C liver samples, a lower or higher expression of a IL8 was found depending on whether the controls were obtained percutaneously or surgically...
  48. doi request reprint Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection
    Patrick Marcellin
    Hopital Beaujon, Clichy, France Electronic address
    Gastroenterology 145:790-800.e3. 2013
    ..We report the efficacy and safety of response-guided therapy with danoprevir (a potent second-generation protease inhibitor), peginterferon alfa-2a (40 KD), and ribavirin in these patients...
  49. ncbi request reprint The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment
    Pierre Pradat
    Department of Hepatology, Hotel Dieu, Lyon, France
    J Med Virol 73:392-6. 2004
    ..This assay is a new reliable alternative for early prediction of virological non-response in patients treated with pegylated interferon/ribavirin...
  50. ncbi request reprint Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C
    Tarik Asselah
    Service d hépatologie and INSERM CRB3, AP HP Hôpital Beaujon, University of Paris VII, Paris, France
    Gastroenterology 129:2064-75. 2005
    ....
  51. ncbi request reprint [Chronic hepatitis B: which patients should be treated and how?]
    Tarik Asselah
    Hepatologie, INSERM U481, Hopital Beaujon, Clichy, France
    Gastroenterol Clin Biol 29:374-83. 2005
  52. ncbi request reprint Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, INSERM Unité 481, and Centre de Recherches Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    N Engl J Med 348:808-16. 2003
    ..In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against hepatitis B virus (HBV), including lamivudine-resistant strains...
  53. doi request reprint High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials
    Patrick Marcellin
    Service d Hepatologie, Hopital Beaujon, APHP, University Paris Diderot and INSERM CRB3, Clichy, France
    Hepatology 56:2039-50. 2012
    ..0-66.6%) among genotype 3 patients; and 59.4% (95% CI: 40.6-76.3%), 63.3% (95% CI: 54.3-71.6%), and 54.3% (95% CI: 47.5-60.9%) among genotype 4 patients. The absence of a VR by week 12 had the highest negative PV across all genotypes...
  54. doi request reprint Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C
    Ana Carolina Cardoso
    Service d Hépatologie and INSERM U773 CRB3, Hopital Beaujon, APHP, University of Paris 7, Clichy, France
    Liver Int 32:612-21. 2012
    ..A secondary analysis was performed to assess whether or not alanine aminotransferase (ALT) levels would impact on the accuracy of TE...
  55. doi request reprint Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C
    Rami Moucari
    Service d Hépatologie et INSERM U773 CRB3, Hopital Beaujon, Clichy, France
    Gut 59:1694-8. 2010
    ..The aim of this study was to evaluate the short-term effect of an HCV protease inhibitor monotherapy on IR in parallel with an antiviral effect...
  56. ncbi request reprint High rate of adefovir-lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients
    Patrick Marcellin
    Hopital Beaujon, Service d Hepatologie, Clichy, France
    Eur J Gastroenterol Hepatol 22:1290-6. 2010
    ..This study describes the types of therapy used in chronic hepatitis B (CHB) in France and patient characteristics according to therapy...
  57. ncbi request reprint Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C
    Patrick Marcellin
    Hopital Beaujon, Service d Hepatologie, 100 Bld du General Leclerc, 92100 Clichy, France
    J Hepatol 47:476-83. 2007
    ..In the hepatitis C virus (HCV) replicon system, merimepodib (MMPD), a novel, selective inhibitor of inosine monophosphate dehydrogenase, has shown potent antiviral effects...
  58. ncbi request reprint Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University Paris 7, Hopital Beaujon, Clichy, France
    J Hepatol 47:580-7. 2007
    ..32% with 48 weeks, P=0.014). Patients are best served by quantitative determination of the hepatitis C virus RNA level at weeks 4, 12 and 24. The results of these determinations can then be used to tailor the length of therapy...
  59. doi request reprint Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients
    Michelle Martinot-Peignoux
    Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U 773 and Service d Hépatologie Hôpital Beaujon APHP, Universite Paris Diderot, 92110 Clichy, France
    J Hepatol 58:1089-95. 2013
    ..Therefore, we investigated these relationships in a large cohort of unselected, well-characterized, treatment-naïve CHB patients...
  60. ncbi request reprint A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    Hepatology 40:140-8. 2004
    ..The pharmacokinetic profile of clevudine was proportional to the dose. In conclusion, these results demonstrate the tolerability and potent activity of clevudine in HBV-infected patients and support further clinical study...
  61. doi request reprint Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease
    Pierre Nahon
    AP HP, Service d Hepato Gastroenterologie, Hopital Jean Verdier, Avenue du 14 Juillet, 93143 Bondy, France
    J Hepatol 49:1062-8. 2008
    ..The aim of this study was to assess the accuracy of liver stiffness measurement (LSM) for the diagnosis of extensive fibrosis and cirrhosis in patients with alcoholic liver disease (ALD)...
  62. pmc Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
    Tarik Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, Paris, France
    Liver Int 30:1259-69. 2010
    ..The goal of this review is to present the mechanisms of non-response, to overcome it and to identify factors that can help to predict the response to anti-HCV therapy...
  63. ncbi request reprint Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C
    Tarik Asselah
    Service d Hépatologie and INSERM U773, CRB3, University of Paris VII, AP HP Hôpital Beaujon, Clichy, France
    Semin Liver Dis 27:13-27. 2007
    ..This article reviews genetic, genomic, and proteomic aspects associated with the natural history of HCV infection (i.e., viral clearance, fibrosis progression) and the response to therapy...
  64. doi request reprint Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy
    Thierry Poynard
    Service d Hepatologie, Université Pierre et Marie Curie Liver Center, hôpital La Pitié Salpêtrière, Paris, France
    Gastroenterology 136:1618-28.e2. 2009
    ..Alternate options are needed for patients who relapse or do not respond to therapy...
  65. ncbi request reprint Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up
    Corinne Castelnau
    Service d Hepatologie, Hopital Beaujon, AP HP INSERM U773 CRB3, Clichy, and Université Paris 13, Bobigny, France
    Hepatology 44:728-35. 2006
    ..The follow-up of HDV-RNA levels during therapy, which allows the differentiation of various profiles of virological responses, improves treatment monitoring...
  66. pmc Changes in autophagic response in patients with chronic hepatitis C virus infection
    Pierre Emmanuel Rautou
    Service d Hepatologie, Hopital Beaujon, Assistance Publique Hopitaux de Paris, Clichy, France
    Am J Pathol 178:2708-15. 2011
    ..Neither genotype nor viral load influenced the autophagy level. In conclusion, autophagy is altered in hepatocytes from CHC patients, likely due to a blockade of the last step of the autophagic process...
  67. ncbi request reprint Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C
    David Saadoun
    Service de Médecine Interne and CNRS UMR 7087, Hopital Pitie Salpetriere, Paris, France
    Hepatology 43:1337-45. 2006
    ..001), and steatosis higher than 10% (P = .04). In conclusion, our study shows an independent association between cryoglobulin and steatosis as well as advanced fibrosis...
  68. doi request reprint Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G
    Olivier Lada
    Service d Hépatologie and INSERM U773 CRB3, AP HP Hôpital Beaujon, Clichy, France
    Liver Int 32:93-101. 2012
    ..To evaluate the early virological response (EVR) to combined tenofovir-lamivudine or emtricitabine regimen in HBV/HIV-co-infected patients and the long-term efficacy of tenofovir...
  69. ncbi request reprint Interferon therapy for chronic hepatitis B
    Tarik Asselah
    Service d Hepatologie, INSERM U773, CRB3, University of Paris VII, Hopital Beaujon, 92110 Clichy, France
    Clin Liver Dis 11:839-49, viii. 2007
    ..This article summarizes the results obtained with interferon alfa and pegylated interferon alfa, as monotherapy and in combination with lamivudine, in the treatment of chronic hepatitis B...
  70. doi request reprint Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes
    Magali Sasso
    R and D Department, Echosens, Paris, France
    Ultrasound Med Biol 36:1825-35. 2010
    ..Furthermore, results show that CAP can efficiently separate several steatosis grades. These promising results suggest that CAP is a noninvasive, immediate, objective and efficient method to detect and quantify steatosis...
  71. pmc Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy
    Liana Codes
    Service d Hepatologie, University of Paris VII, AP HP Hôpital Beaujon, Clichy, France
    Gut 56:390-5. 2007
    ..The aim of this study was to evaluate the severity of chronic hepatitis C in women, in relation to the menopause, steatosis and hormone replacement therapy (HRT)...
  72. ncbi request reprint Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients
    Adrien Kettaneh
    Service de Medecine Interne, Hopital Saint Antoine, Assistance Publique Hopitaux de Paris, Paris and Université Pierre et Marie Curie, Paris, France
    J Hepatol 46:628-34. 2007
    ..We investigated features associated with success rate of shots, and performance of FibroScan for the diagnosis of cirrhosis...
  73. doi request reprint New direct-acting antivirals' combination for the treatment of chronic hepatitis C
    Tarik Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, and Service d Hépatologie, Hopital Beaujon, Clichy, France
    Liver Int 31:68-77. 2011
    ..There is ongoing development of new molecules such as HCV enzyme inhibitors. The aim of this review is to summarize the results obtained with DAAs: protease and polymerase inhibitors...
  74. doi request reprint Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B
    Patrick Marcellin
    Service d Hépatologie and INSERM U 773, Hopital Beaujon, AP HP, University of Paris, Clichy, France
    Liver Int 29:242-7. 2009
    ..This study aims to assess its diagnosis accuracy in patients with chronic hepatitis B...
  75. doi request reprint Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT
    Maxime Ronot
    Unit for Training and Research in Medicine, Universite Paris 7 Denis Diderot, Paris, France
    Radiology 256:135-42. 2010
    ..To prospectively assess the utility of perfusion computed tomography (CT) for differentiating minimal from intermediate fibrosis in treatment-naïve patients with chronic hepatitis C virus (HCV) infection...
  76. doi request reprint Protease and polymerase inhibitors for the treatment of hepatitis C
    Tarik Asselah
    INSERM, U773, Centre de Recherche Bichat Beaujon CRB3, Service d Hepatologie, Hopital Beaujon, Clichy, France
    Liver Int 29:57-67. 2009
    ..The development of new molecules such as HCV enzyme inhibitors is ongoing. The aim of this review is to summarize results obtained with STATC: protease and polymerase inhibitors...
  77. ncbi request reprint Acute hepatitis E with severe jaundice: report of three cases
    Rami Moucari
    Hepatology Department and INSERM U773, CRB3, University of Paris VII, Beaujon Hospital, Clichy, France
    Eur J Gastroenterol Hepatol 19:1012-5. 2007
    ..HEV-RNA detection by real-time reverse transcriptase-PCR is a very efficacious diagnostic tool in anti-HEV immunoglobulin-M-negative cases...
  78. ncbi request reprint Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C
    M Martinot-Peignoux
    INSERM U481, Service d Hepatologie, Hopital Beaujon, Clichy, France
    J Viral Hepat 13:701-7. 2006
    ..A week 4 stopping rule for patients with chronic hepatitis C treated with peginterferon with ribavirin might be proposed by using the model developed in our study...
  79. pmc SCG10 expression on activation of hepatic stellate cells promotes cell motility through interference with microtubules
    Valerie Paradis
    Department of Pathology, INSERM U773, the Serviced Hépatologie, Beaujon Hospital, AP HP, University Paris Diderot, Paris, France
    Am J Pathol 177:1791-7. 2010
    ..SCG10 may represent a potential molecular target for anti-fibrosis therapies...
  80. ncbi request reprint Solitary pulmonary metastasis arising thirteen years after liver transplantation for HBV-related hepatocellular carcinoma
    Chiara Viola
    Service d Hepatologie, INSERM CRB3, University of Paris VII, Hopital, Beaujon, Clichy 92 110, France
    World J Gastroenterol 12:4911-3. 2006
    ..Many HCCs grow slowly, and the growth rate of recurrent tumors in patients receiving immunosuppressive therapy is significantly greater than that of those who do not receive immunosuppressive therapy...
  81. ncbi request reprint [Treatment of patients with chronic hepatitis C who have not been previously treated]
    Patrick Marcellin
    Service d Hepatologie, INSERM U 481 et Centre Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy
    Gastroenterol Clin Biol 26:B194-201. 2002
  82. ncbi request reprint The current status of antiviral therapy of chronic hepatitis B
    Tarik Asselah
    Seroice d Hépatologie and INSERM CRB3, Unioersity Paris 7, Hopital Beaujon, AP HP, Clichy, France
    J Clin Virol 34:S115-24. 2005
    ....
  83. ncbi request reprint [New management strategies for hepatitis B]
    Corinne Castelneau
    Service d Hepatologie, Inserm U 481 et Centre de recherche Claude Bernard sur les hépatites virales, Hopital Beaujon, Clichy, France
    Gastroenterol Clin Biol 26:120-2. 2002
  84. ncbi request reprint Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C
    Michel Tod
    Department of Pharmacy, Cochin St Vincent de Paul Hospital, Paris, France
    Clin Pharmacokinet 44:417-28. 2005
    ..Interferon (IFN)-alpha and ribavirin combination therapy is the standard treatment for patients with chronic hepatitis C. However, ribavirin induces anaemia, especially by haemolysis, an adverse effect that is dose-limiting...
  85. ncbi request reprint [Steatosis during chronic hepatitis C: the role of insulin resistance and viral factors]
    Rami Moucari
    Pôle des Maladies de l Appareil Digestif, Service d Hépatologie et INSERM U773 CRB3, Universite Paris VII, Hopital Beaujon, Clichy
    Gastroenterol Clin Biol 31:643-54. 2007
    ..Insulin resistance and steatosis, appear to be associated with fibrosis progression and impairment of sustained response to antiviral treatment...
  86. ncbi request reprint Advances in therapy for chronic hepatitis B
    Patrick Marcellin
    Service d Hépatologie and INSERM 0481, Hopital Beaujon, Clichy, France
    Semin Liver Dis 22:33-6. 2002
    ..Adefovir dipivoxil's effects include rapid and sustained virological, serological, histological, and biochemical responses, with minimal adverse effects. Significant histological improvement was seen in all patient subgroups at 48 weeks...
  87. ncbi request reprint Clevudine: a promising therapy for the treatment of chronic hepatitis B
    Tarik Asselah
    Universite Paris 7 Denis Diderot, Hopital Beaujon, Pôle des Maladies de l Appareil Digestif, Service d Hepatologie, Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U773
    Expert Opin Investig Drugs 17:1963-74. 2008
    ..This article reviews chronic HBV and its therapy options. Specifically, it describes clevudine's potent and sustained antiviral activity as observed in vitro and in vivo...
  88. ncbi request reprint Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC
    Christophe Corpechot
    Service d Hepatologie, Centre national de référence des maladies inflammatoires du foie et des voies biliaires, Hopital Saint Antoine, Paris, France
    Hepatology 43:1118-24. 2006
    ..In conclusion, transient elastography is a simple and reliable noninvasive means for assessing biliary fibrosis. It should be a promising tool to assess antifibrotic therapies in PBC or PSC...
  89. ncbi request reprint Auxiliary liver transplantation for fulminant hepatitis B: results from a series of six patients with special emphasis on regeneration and recurrence of hepatitis B
    Francois Durand
    Service d Hépatologie and INSERM U481, Hopital Beaujon, Clichy, France
    Liver Transpl 8:701-7. 2002
    ..Finally, the remnant part of the native liver does not compromise immunization against HBV...
  90. pmc Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study
    Patrice Cacoub
    Department of Internal Medicine, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, Paris cedex 13 F 75651, France
    World J Gastroenterol 14:6195-203. 2008
    ....
  91. ncbi request reprint Long-term outcome of hepatitis C infection after bone marrow transplantation
    Regis Peffault De Latour
    Service d hématologie greffe de moelle, the Université Paris VII, Paris, France
    Blood 103:1618-24. 2004
    ..Systematic detection of HCV infection, liver biopsy, and therapeutic intervention are therefore warranted in long-term marrow transplant recipients...
  92. ncbi request reprint [Treatment of chronic hepatitis B]
    Tarik Asselah
    Hopital Beaujon, Service d Hepatologie, AP HP, 92110 Clichy
    Rev Prat 61:45-51. 2011
    ..Telbivudine is more potent and has a lower rate of resistance than lamivudine but the resistance rate is significantly higher than other approved drugs. Tenofovir has a potent antiviral effect with a good resistance profile...
  93. ncbi request reprint [Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]
    Tarik Asselah
    Service d Hépatologie et Unité INSERM CRB3, Universite Paris VII
    Gastroenterol Clin Biol 30:1281-95. 2006
    ..In this article we present a comprehensive review of post-transplant hepatitis C virus infection; in particular fibrosis progression and the major challenges according to treatment...
  94. doi request reprint Allogeneic hematopoietic cell transplant in HCV-infected patients
    Regis Peffault De Latour
    Service d Hématologie Greffe, Hopital Saint Louis, 75475 Paris, France
    J Hepatol 48:1008-17. 2008
    ..The pathophysiology of liver fibrosis is discussed as well as the present recommended therapy in this particular population...
  95. ncbi request reprint HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C
    Vincent Di Martino
    Service d Hepatologie, INSERM U481 et Centre de Recherche Claude Bernard sur les hépatites virales, 100 bd du Général Leclerc, Hopital Beaujon, 92110 Clichy, France
    AIDS 16:441-5. 2002
    ..We compared histological responses to interferon (IFN) alpha therapy between HIV-positive and HIV-negative injecting drug users (IDU) and determined factors associated with histological response...
  96. ncbi request reprint [Treatment of chronic hepatitis B]
    Tarik Asselah
    Service d Hepatologie, INSERM U481, Hopital Beaujon, 92110 Clichy
    Gastroenterol Clin Biol 28:1215-27. 2004